EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Hepatitis C treatment outcome among people in prison: The SToP ‐C study

Hannah Ryan iD, Gregory J Dore iD, Jason Grebely iD, Marianne Byrne, Evan B Cunningham iD, Marianne Martinello iD, Andrew R Lloyd iD, Behzad Hajarizadeh iD

Liver International · 2024-11 · 44 (11) · 2996-3007

DOI: 10.1111/liv.16074 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, online erschienen am 27.08.2024. Verfasst von Hannah Ryan und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Antiviral Agents, Sustained Virologic Response, Prisoners, Sofosbuvir. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Hepatitis C virus (HCV) burden is higher among people in prison given high prevalence of injecting drug use. This study evaluated direct‐acting antiviral (DAA) treatment outcome in prisons.

Methods

The Surveillance and Treatment of Prisoners with hepatitis C (SToP‐C) study enrolled individuals incarcerated in four Australian prisons (2017–2019). Participants with detectable HCV RNA were offered sofosbuvir‐velpatasvir for 12 weeks. Sustained virological response (SVR) was assessed in intention‐to‐treat (ITT; participants commencing treatment and due for SVR assessment before study close) and per‐protocol (PP; participants with documented treatment completion and SVR assessment) populations.

Results

Among 799 participants with HCV, 324 (41%) commenced treatment (94% male; median age, 32 years; median duration of incarceration, 9 months). In ITT population ( n = 310), 201 had documented treatment completion (65% [95% CI: 59–70]), and 137 achieved SVR (ITT‐SVR: 44% [95% CI: 39–50]). In PP population ( n = 143), 137 achieved SVR (PP‐SVR: 96% [95% CI: 91–98]). Six participants had quantifiable HCV RNA at SVR assessment from treatment failure ( n = 2) or reinfection ( n = 4). Release or inter‐prison transfer was common reasons for no documented treatment completion ( n = 106/109 [97%]) and no SVR assessment ( n = 57/58 [98%]). In ITT analysis, longer incarceration was associated with increased SVR (adjusted OR per month 1.03 [95% CI: 1.01–1.04]).

Conclusion

Among participants who completed DAA treatment and were assessed for SVR, treatment outcome was consistent with non‐prison clinical studies. However, most individuals did not complete treatment or lacked study‐documented treatment outcome due to release or transfer. Strategies to accommodate dynamic prisoner populations are required to ensure continuity of HCV care, including treatment completion and post‐treatment care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsSustained Virologic ResponsePrisonersSofosbuvirHepacivirusHumansMaleFemaleAdultAustraliaHeterocyclic Compounds, 4 or More RingsMiddle AgedTreatment OutcomeDrug CombinationsHepatitis C, ChronicHepatitis CRNA, ViralPrisonsCarbamates

Stichwörter der Autor:innen

HCVdirect‐acting antiviralpeople who inject drugsprisonsustained virological responsetreatment

Substanzen

Antiviral AgentsSofosbuvirHeterocyclic Compounds, 4 or More Ringssofosbuvir-velpatasvir drug combinationDrug CombinationsRNA, ViralCarbamates

Autor:innen und Institutionen

  • The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.

ORCID-Profile: Hannah Ryan, Gregory J Dore, Jason Grebely, Evan B Cunningham, Marianne Martinello, Andrew R Lloyd, Behzad Hajarizadeh

Förderung

  • Gilead Sciences
  • National Health and Medical Research Council

Zitieren

APA

Ryan, H., Dore, G. J., Grebely, J., Byrne, M., Cunningham, E. B., Martinello, M., Lloyd, A. R., & Hajarizadeh, B. (2024). Hepatitis C treatment outcome among people in prison: The SToP ‐C study. Liver International, 44(11), 2996-3007. https://doi.org/10.1111/liv.16074

Vancouver

Ryan H, Dore GJ, Grebely J, Byrne M, Cunningham EB, Martinello M, et al. Hepatitis C treatment outcome among people in prison: The SToP ‐C study. Liver International. 2024;44(11):2996-3007. doi:10.1111/liv.16074

BibTeX
@article{Ryan2024,
  author = {Ryan, Hannah and Dore, Gregory J and Grebely, Jason and Byrne, Marianne and Cunningham, Evan B and Martinello, Marianne and Lloyd, Andrew R and Hajarizadeh, Behzad},
  title = {Hepatitis C treatment outcome among people in prison: The SToP ‐C study},
  journal = {Liver International},
  year = {2024},
  volume = {44},
  number = {11},
  pages = {2996--3007},
  doi = {10.1111/liv.16074}
}
Kostenlos starten →